The Effects of Gemfibrozil on Hyperlipidemia in Children With Persistent Nephrotic Syndrome

dc.contributor.authorBüyükçelik, M.
dc.contributor.authorAnarat, A.
dc.contributor.authorBayazıt, Aysun Karabay
dc.contributor.authorNoyan, A,
dc.contributor.authorÖzel, A.
dc.contributor.authorAnarat, R.
dc.contributor.authorAydıngülü, H.
dc.date.accessioned2020-03-26T16:44:54Z
dc.date.available2020-03-26T16:44:54Z
dc.date.issued2002
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractPersistent nephrotic syndrome is frequently accompanied by severe hyperlipidemia, and this may pose a substantial risk for cardiovascular disease. Lipid-lowering drugs are prescribed by many nephrologists for adult patients but rarely for nephrotic children. The present investigation was designed to evaluate the safety and efficacy of gemfibrozil in nephrotic children. Eight girls and four boys aged from 5 to 17 years were enrolled in this study. They were all steroid and immunosuppressive resistant patients with nephrotic range proteinuria. Placebo was administered to five patients and gemfibrozil was administered to seven patients for four months. Blood samples were taken for the determination of cholesterol, triglyceride, low-density lipoprotein (LDL), high-density lipoprotein (HDL), BUN, serum creatinine (S-cr), ALT, AST, CPK, apolipoprotein A (apo A), apoliporotein B (apo B), and serum albumin levels during the initial and subsequent examinations. At the end of the fourth month, gemfibrozil reduced total cholesterol by 34%, LDL by 30%, apo B by 21% and triglycerides by 53% (p < 0.05). HDL cholesterol and apo A levels were not significantly altered. Renal function and urine protein excretion were not affected by gemfibrozil. In this study gemfibrozil therapy had no side effects and had favorable effects on the lipoprotein profile of nephrotic patients.en_US
dc.identifier.citationBüyükçelik, M., Anarat, A., Bayazıt, A. K., Noyan, A., Özel, A., Anarat, R., Aydıngülü, H., (2002). The Effects of Gemfibrozil on Hyperlipidemia in Children With Persistent Nephrotic Syndrome. Turkish Journal of Pediatrics, 44(1), 40-44.
dc.identifier.endpage44en_US
dc.identifier.issn0041-4301en_US
dc.identifier.issue1en_US
dc.identifier.pmid11858378en_US
dc.identifier.startpage40en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12395/18067
dc.identifier.volume44en_US
dc.identifier.wosWOS:000173860500009en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTurkish J Pediatricsen_US
dc.relation.ispartofTurkish Journal of Pediatricsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectAntilipid Therapyen_US
dc.subjectChildhooden_US
dc.subjectGemfibrozilen_US
dc.subjectNephrotic Syndromeen_US
dc.titleThe Effects of Gemfibrozil on Hyperlipidemia in Children With Persistent Nephrotic Syndromeen_US
dc.typeArticleen_US

Dosyalar